More Videos
|
CNBC'S MOST SHARED
- Investing in Tech Now
- Apartment Vacancy Rate Hits 22-Year High
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Software Giants Rush to Cash In on Carbon-Trading
- Preparing for Retirement
- China Demands Currency Reform, France Backs Debate
- Google's Eric Schmidt on Yahoo's Bing
- Playing by Different Rules
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- July 10th in Market History
- Microsoft Plays a Game of Bing Pong
- Options Smell 'Blood' on Infosys
- Christmas in July: Consumers To Out-Scrooge Scrooge
- GM's Second Chance
- Art Cashin: Traders Weigh Obama Policy Changes
- Warren Buffett: Economy Needs Another Dose of Viagra
.ll_medium.jpg)
- SEC, CFTC to Police Over-the Counter Derivatives
- AIG Prepares to Pay More Bonuses to Executives
- China Demands Currency Reform, France Backs Debate
- IEA Sees Global Oil Demand Bouncing Back in 2010
- UBS Can't Comply with US Request: Internal Memo
- Treasury Sold Warrants Below Market Value: Panel
- New Inquiries into Murdoch Paper Phone Hacking Case?
- China Accuses Rio Staff of Bribing Steelmakers
- Assets Are Less Toxic, but Banks Have Other Troubles
RSS FEED
Text Size 
 |
Yoda |
At the end of his speech in the opening session, the outgoing president of the organization played a "Star Wars" clip with the sage saying, "Try not. Do or do not. There is no try." He was trying to make a point about the ACC's role in forging healthcare reform.
But many--especially, I suspect, folks at Merck [MRK
Loading...
()
] and Schering-Plough-[SGP
Loading...
()
] --would argue the ACC tried, but did not do when it comes to the promised "reasoned" panel discussion of the controversial Vytorin/Zetia test results.
It was standing room only in the great hall for the "showcase session," although the fire marshal shooed away people who were standing four and five deep in the wide doorways. They came to hear the data presentation and then an airing-out of the results by an ACC handpicked panel of experts.
But the second part never happened. One of the experts, Dr. Harlan Krumholz, launched into prepared remarks during which he suggested that Zetia could be nothing more than an "expensive placebo." Those are his words. Another panel member put a brief button on Dr. Krumholz's speech and that was it. No discussion. No q and a. The room, packed with by my estimate about 6,000 people, emptied out in a hurry.
Damage was done.
Credit Suisse analyst Catherine Arnold writes in a research note to clients this morning, "...the expected 'panel discussion' had almost no 'discussion', rather it seemed like a (Zetia)-bashing session...." Because of that Arnold now believes a Vytorin/Zetia "recovery" will require patience and as a result she's taking a scalpel to her earnings estimates for both companies.
Credit Suisse has done and wants to do more investment banking for MRK and SGP. And Arnold or someone on her team lives with a Schering employee.
May the sales force be with Merck and Schering-Plough.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes